Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 27;14(17):3543.
doi: 10.3390/nu14173543.

Chemosensory Functions in Patients with Inflammatory Bowel Disease and Their Association with Clinical Disease Activity

Affiliations

Chemosensory Functions in Patients with Inflammatory Bowel Disease and Their Association with Clinical Disease Activity

Xingyu Han et al. Nutrients. .

Abstract

Purpose: Decreased olfactory and gustatory functions are present in various systemic autoimmune diseases. However, little is known about the chemosensory functions of patients with inflammatory bowel disease (IBD). The present study aimed to investigate olfactory and gustatory functions in patients with IBD and their correlation with clinical disease activity. Methods: A total of 103 patients with IBD were included (52 men, 51 women, mean age 40.3 ± 1.2 years) in the present study. Chemosensory functions were assessed utilizing the “Sniffin’ Sticks” olfactory function test and “taste sprays” gustatory function test. The clinical disease activity of patients was graded as remission, mild, and moderate−severe. In addition, inflammatory markers (fecal calprotectin, C-reactive protein and blood leucocyte count) were recorded. Results: In total, 70% of IBD patients were normosmic, 30% were hyposmic, and none of them was functionally anosmic; 6% of the patients showed signs of hypogeusia. Patients with moderate−severe IBD reached a higher olfactory threshold score compared with patients with remission (p = 0.011) and mild IBD (p < 0.001). The BMI of IBD patients was inversely correlated with their olfactory threshold (r = −0.25, p = 0.010). Olfactory and gustatory function in IBD patients did not correlate with duration of disease, blood leucocyte count, CRP level, or fecal calprotectin level. However, patients’ olfactory function significantly increased after 4 months of TNF-α inhibitor treatment (p = 0.038). Conclusions: IBD patients are more likely to present with hyposmia. Olfactory thresholds were mainly affected. They were significantly associated with clinical disease activity and BMI. As shown in a subgroup, treatment with TNF-α inhibitors appeared to improve olfactory function.

Keywords: autoimmune diseases; inflammatory bowel disease; olfactory and gustatory function; smell disorder; taste disorder.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Patients with moderate–severe IBD reached higher olfactory threshold scores compared to patients with remission and mild IBD. * p < 0.05; *** p < 0.001.
Figure 2
Figure 2
The correlation between olfactory threshold scores and BMI.

Similar articles

Cited by

References

    1. Alatab S., Sepanlou S.G., Ikuta K., Vahedi H., Bisignano C., Safiri S., Sadeghi A., Nixon M.R., Abdoli A., Abolhassani H., et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 2020;5:17–30. doi: 10.1016/S2468-1253(19)30333-4. - DOI - PMC - PubMed
    1. Zhang Y.Z., Li Y.Y. Inflammatory bowel disease: Pathogenesis. World J. Gastroenterol. 2014;20:91–99. doi: 10.3748/wjg.v20.i1.91. - DOI - PMC - PubMed
    1. Marotto D., Atzeni F., Ardizzone S., Monteleone G., Giorgi V., Sarzi-Puttini P. Extra-intestinal manifestations of inflammatory bowel diseases. Pharmacol. Res. 2020;161:105206. doi: 10.1016/j.phrs.2020.105206. - DOI - PubMed
    1. Gluch P., Swiatek A., Dudek P., Fabisiak A., Talar-Wojnarowska R. Neurological Manifestations and Psychiatric Disorders in the Course of Inflammatory Bowel Diseases. J. Gastrointest. Liver Dis. 2022;31:107–118. doi: 10.15403/jgld-3965. - DOI - PubMed
    1. Armstrong A.W., Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323:1945–1960. doi: 10.1001/jama.2020.4006. - DOI - PubMed

Substances